Alternative Method to Determine Specific Activity of Lu-177 by HPLC

被引:12
|
作者
Breeman, Wouter A. P. [1 ]
de Zanger, Rory M. S. [1 ]
Chan, Ho Sze [1 ]
de Blois, Erik [1 ]
机构
[1] Erasmus MC, Dept Nucl Med, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands
关键词
Lu-177-DOTA-TATE; DOTA-peptides; HPLC; Lutetium-177; specific activity; titration;
D O I
10.2174/1874471008666150312162340
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177-DOTA-peptides requires Lu-177 with high specific activity (SA) and values >740 GBq Lu-177 per mg Lu to maximise the atom% of Lu-177 over total Lu. Vendors provide SA values which are based on activity and mass of the target, whereas due to "burn-up" of target, these SA values are not accurate. For a radiochemist the SA of Lu-177 is of interest prior to radiolabeling. An alternative method to determine SA was developed by HPLC, which includes a metal titration of a known amount of DOTA-peptide with a known amount of activity (Lu-177), and a unknown amount of metal (Lu177+nat). Based on an HPLC separation of radiometal-DOTA-peptide and DOTA-peptide, and the concordant ratio of these components the metal content (Lu177+nat) can be calculated, and eventually the SA of Lu-177 can be accurately determined. These experimentally determined SA values exceeded the estimated values provided by vendors by 27 +/- 16%, (range 6-73 %). The deviation of SA values for samples from the same Lu batch was <2% (n >= 10). In conclusion: the SA of Lu-177 is apparently often higher as stated by vendors in comparison to the experimentally determined actual values. For this reason, the SA of Lu-177-DOTA-TATE and other Lu-DOTA-peptides could be increased accordingly.
引用
收藏
页码:119 / 122
页数:4
相关论文
共 50 条
  • [41] Calibration Procedures for Radionuclide Calibrators to Achieve Traceable Activity Measurements for Lu-177
    Reijonen, V.
    Toroi, P.
    Tenhunen, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S12 - S13
  • [42] The Optimization of the Current ININ Method of Lu-177 DOTA-HYNIC-iPSMA
    Omar, Y.
    Atteya, Y.
    Taha, N.
    AbdelKawi, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S780 - S780
  • [43] STUDY OF REACTION LU-176(N,GAMMA)LU-177)
    MICHAUD, B
    KERN, J
    SCHALLER, LA
    HELVETICA PHYSICA ACTA, 1970, 43 (05): : 424 - &
  • [44] PRODUCTION OF GMP LU-177 NCA FOR RADIOPHARMACEUTICAL APPLICATIONS
    Harfensteller, M.
    Marx, S.
    Henkelmann, R.
    Kuefner, J.
    Zhernosekov, K.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 8 - 8
  • [45] Lu-177 Labeled RGD peptide for Tumor Targeting
    Hong, Y.
    Lee, S.
    Choi, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S318 - S318
  • [46] Effect of Reconstruction Parameters on Lu-177 SPECT Imaging
    Parlak, Y.
    Goksoy, D.
    Sezgin, C.
    Mutevelizade, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S203 - S204
  • [47] NUCLEAR ORIENTATION OF LU-177 IN IRON, COBALT AND NICKEL
    KEUS, HE
    HUISKAMP, WJ
    PHYSICA B & C, 1976, 85 (01): : 137 - 141
  • [48] Clinical Implementation of FDA Approved Radiopharmaceutical Lu-177
    George, S.
    George, J.
    Mishra, V.
    Chuong, M.
    Gutierrez, A.
    MEDICAL PHYSICS, 2019, 46 (06) : E544 - E544
  • [49] Chemistry and Bifunctional Chelating Agents for Binding Lu-177
    Parus, Jozef L.
    Pawlak, Dariusz
    Mikolajczak, Renata
    Duatti, Adriano
    CURRENT RADIOPHARMACEUTICALS, 2015, 8 (02) : 86 - 94
  • [50] Lu-177 SPECT/CT quantification on a Symbia T
    Vanderlinden, B.
    Marin, G.
    Guiot, T.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S313 - S313